Core Viewpoint - Novo Nordisk has successfully integrated AI tools, specifically Anthropic's Claude, into the drafting of clinical research reports, significantly reducing the time and cost associated with this process [3][5]. Group 1: AI Integration and Efficiency - Novo Nordisk began testing AI models, including Claude 3.5 Sonnet, to assist in drafting regulatory documents for drug approvals [4]. - The use of AI has reduced the drafting time for clinical research reports from approximately 15 weeks to under 10 minutes [5]. - Previously, over 50 writers were involved in drafting these documents, but now only 3 human writers are needed with the assistance of Claude [5]. Group 2: Cost Implications - The annual expenditure on Claude is less than the salary of a single writer, indicating significant cost savings for the company [5]. - Although there are no current layoffs among writers, the company plans to reduce new hiring and reallocate saved resources to other departments [5]. Group 3: Error Reduction and Human Oversight - The strategic director noted a significant decrease in error rates when using AI for document drafting [3]. - A common method to reduce AI error rates, known as retrieval-augmented generation (RAG), is employed, where human experts provide feedback to improve AI outputs [5]. - This practice allows for the reuse of accurate definitions and descriptions in future documents, enhancing overall efficiency [5].
AI获医药巨头认可!诺和诺德:AI终于足够可靠,可以生成敏感文件